Advertisement
GILD vs NVS
Which Stock Would AI Choose? Gilead Sciences (GILD) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- Gilead Sciences (GILD) and Novartis (NVS) both operate in the biopharmaceutical sector, with NVS boasting a larger market capitalization of approximately $280 billion compared to GILD's $163 billion.
- NVS offers a higher dividend yield at 3.23% versus GILD's 2.49%, appealing to income-focused investors.
- Year-to-date (YTD) performance shows NVS slightly ahead at 8.87% compared to GILD's 7.87%, with one-year returns of 33.08% and 30.90%, respectively.
- Both stocks trade at similar price-to-earnings (P/E) ratios around 20, indicating comparable valuations relative to earnings.
- GILD exhibits lower volatility with a beta of 0.33, versus NVS's 0.52 (beta measures stock volatility relative to the market).
- Recent pipeline advancements, including regulatory reviews and R&D expansions, support sentiment for both in the competitive pharma landscape.
Introduction
This stock comparison examines GILD and NVS, two established biopharmaceutical giants navigating evolving market dynamics in virology, oncology, and beyond. Investors seeking exposure to healthcare innovation, stable dividends, or defensive positioning amid economic uncertainty may find value in analyzing their relative performance. With both companies reporting solid profitability and pipeline progress, this analysis highlights key metrics, recent momentum, and strategic differences to inform portfolio decisions in the current environment.
GILD Overview and Recent Performance
Gilead Sciences (GILD), headquartered in Foster City, California, specializes in treatments for HIV/AIDS, hepatitis, oncology, and inflammatory diseases. Its portfolio includes blockbuster drugs like Biktarvy for HIV and Veklury for COVID-19. In recent market activity, GILD shares have shown resilience, trading around $131 with a year-to-date gain of 7.87%. Sentiment has been influenced by FDA priority reviews for new HIV therapies and strategic acquisitions bolstering its oncology pipeline, offsetting concerns over slower growth in legacy products. The stock's low beta of 0.33 underscores its defensive nature, attracting stability-seeking investors.
NVS Overview and Recent Performance
Novartis AG (NVS), based in Basel, Switzerland, is a diversified global pharma leader with strengths in cardiovascular, immunology, neuroscience, and oncology. Key products include Entresto for heart failure and Cosentyx for psoriasis. Recently, NVS shares hovered near $147, posting an 8.87% YTD increase amid approvals like Health Canada nod for Fabhalta in rare kidney disease and expansions in U.S. manufacturing and R&D. While Q1 sales slightly missed expectations, ongoing biotech deals and AI-driven R&D investments have sustained positive momentum, supporting its larger scale and higher dividend payout.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of 25 top-performing AI trading bots from a library of 351, tailored to current market conditions across sectors like semiconductors, data centers, and ETFs. These bots deliver impressive stats, with annualized returns ranging from 23.53% to 163.10% and win rates between 51.30% and 88.33%. Employing diverse strategies—such as trend trading, swing trades, and volatility plays on multiple tickers—they provide real-time signals for copy trading via virtual or brokerage agents. Explore these high-conviction options to enhance your trading edge.
Head-to-Head Comparison
GILD focuses on specialized virology and cell therapy, driving consistent revenue from HIV franchises but facing patent pressures, while NVS offers broader diversification across therapeutic areas, mitigating single-product risks. Growth drivers differ: GILD leverages oncology acquisitions, NVS emphasizes innovative approvals and R&D scale. Recent momentum favors NVS with superior YTD returns, though GILD provides lower risk via reduced volatility. Sector exposure aligns in pharma, but NVS's international footprint enhances resilience. Market sentiment reflects optimism for both pipelines amid regulatory tailwinds, balanced by industry-wide pricing headwinds.
Tickeron AI Verdict
Tickeron’s AI currently leans toward NVS due to its edge in recent momentum, higher dividend yield, and diversified growth catalysts like regulatory approvals and R&D expansions. While GILD offers superior stability and virology dominance, NVS's relative positioning suggests higher probability of outperformance in the near term, based on trend consistency and market factors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Hold and NVS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GILD’s FA Score shows that 3 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- GILD’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GILD’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- GILD’s TA Score: 4 bullish, 5 bearish.
- NVS’s TA Score: 5 bullish, 4 bearish.
Price Growth
GILD (@Pharmaceuticals: Major) experienced а -1.03% price change this week, while NVS (@Pharmaceuticals: Major) price change was -4.44% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
GILD is expected to report earnings on Jul 30, 2026.
NVS is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GILD | NVS | GILD / NVS | |
| Capitalization | 154B | 282B | 55% |
| EBITDA | 14.5B | 22.4B | 65% |
| Gain YTD | 2.070 | 9.904 | 21% |
| P/E Ratio | 16.84 | 21.07 | 80% |
| Revenue | 29.7B | 56.6B | 52% |
| Total Cash | N/A | 6.98B | - |
| Total Debt | 22.2B | 47B | 47% |
GILD | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 23 | 8 | |
SMR RATING 1..100 | 22 | 27 | |
PRICE GROWTH RATING 1..100 | 58 | 51 | |
P/E GROWTH RATING 1..100 | 78 | 37 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (6) in the Pharmaceuticals Major industry is in the same range as GILD (8) in the Biotechnology industry. This means that NVS’s stock grew similarly to GILD’s over the last 12 months.
NVS's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is in the same range as GILD (23) in the Biotechnology industry. This means that NVS’s stock grew similarly to GILD’s over the last 12 months.
GILD's SMR Rating (22) in the Biotechnology industry is in the same range as NVS (27) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to NVS’s over the last 12 months.
NVS's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as GILD (58) in the Biotechnology industry. This means that NVS’s stock grew similarly to GILD’s over the last 12 months.
NVS's P/E Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for GILD (78) in the Biotechnology industry. This means that NVS’s stock grew somewhat faster than GILD’s over the last 12 months.
| GILD | NVS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 56% | N/A |
| Stochastic ODDS (%) | 3 days ago 54% | 3 days ago 51% |
| Momentum ODDS (%) | 3 days ago 45% | 3 days ago 55% |
| MACD ODDS (%) | 3 days ago 50% | 3 days ago 47% |
| TrendWeek ODDS (%) | 3 days ago 46% | 3 days ago 43% |
| TrendMonth ODDS (%) | 3 days ago 50% | 3 days ago 39% |
| Advances ODDS (%) | 17 days ago 61% | 16 days ago 51% |
| Declines ODDS (%) | 3 days ago 48% | 3 days ago 45% |
| BollingerBands ODDS (%) | 3 days ago 59% | 3 days ago 44% |
| Aroon ODDS (%) | 3 days ago 59% | 3 days ago 47% |
Advertisement
GILD and
Correlation & Price change
A.I.dvisor indicates that over the last year, GILD has been loosely correlated with NVS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To GILD | 1D Price Change % | ||
|---|---|---|---|---|
| GILD | 100% | -1.35% | ||
| NVS - GILD | 48% Loosely correlated | -2.52% | ||
| AMGN - GILD | 45% Loosely correlated | -1.19% | ||
| GSK - GILD | 40% Loosely correlated | -2.84% | ||
| AZN - GILD | 39% Loosely correlated | -1.66% | ||
| BIIB - GILD | 38% Loosely correlated | -1.05% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.